Trusted Resources: News & Meetings
Latest announcements and gatherings
Sanfilippo Ideal for FDA’s Accelerated Approval Pathway, Foundation Says
The Cure Sanfilippo Foundation is encouraging the U.S. Food & Drug Administration (FDA) to consider Sanfilippo syndrome as a candidate for the agency’s accelerated approval pathway. According to a recent foundation-led study, families of Sanfilippo children are willing to accept modest treatment benefits even if they come with risks.
“Doing nothing is the biggest risk in Sanfilippo!” Glenn O’Neill, foundation president and father to a Sanfilippo child, said in a press release. His statement came at the end of a presentation Oct. 20 at the 13th Annual Rare Disease Scientific Workshop.
The FDA’s Accelerated Approval Program allows for earlier approval of therapies that treat serious conditions and fill an unmet medical need. Sanfilippo syndrome, or mucopolysaccharidosis type III (MPS III), is a rare genetic disorder characterized by the mutations in genes that encode enzymes that break down the complex sugar molecule known as heparan sulfate.
BookmarkRelated Content
-
Mucopolysaccharidoses Type I Gene TherapyMucopolysaccharidoses type I (MPS I) is ...
-
Mucopolysaccharidosis (MPS)https://slideplayer.com/slide/17257432/...
-
A Guide to Understanding MPS VI (Maroteaux-Lamy Syndrome)Mucopolysaccharidosis VI (MPS VI) is a v...
-
Believe in G Golf TournamentGianna, was diagnosed with Sanfilippo Sy...
-
Kathleen BuckleyKathleen Buckley is the President of the...
-
Elosulfase Alfa in the Treatment of Mucopolysaccharidosis Type IVA: Insights From the First Managed Access AgreementManaged access agreements provide a cruc...
-
MPS IIIA (Sanfilippo Syndrome, Type A) in a 7-Year-Old Girlhttps://slideplayer.com/slide/13595382/...
Powered by
